Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:12 2024-05-31 am EDT			5-day change	1st Jan Change
3.75 ^GBX	-1.32%		-1.32%	-11.76%

May. 23	Celadon ships to US; Oxford BioDynamics-Goodbody pact	AN
May. 23	Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic	CI

Fusion Antibodies plc Announces Board Changes

August 16, 2018 at 02:00 am EDT

At the time of the AIM admission, two of Fusion Antibodies plc's long-standing non-executive directors, Sir John Cadogan and David Moore, stepped down from the board. Immediately after the IPO, Tim Watts was appointed as a non-executive director and became Chair of the Audit Committee.

Latest news about Fusion Antibodies plc

Celadon ships to US; Oxford BioDynamics-Goodbody pact	May. 23	AN
Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic	May. 23	CI
EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	Apr. 30	AN
Fusion Antibodies inks commercial contract for OptiPhage library	Apr. 15	AN
Fusion Antibodies Secures Contract to Set Up OptiPhage Library	Apr. 15	MT
Fusion Antibodies plc Enters into Commercial Contract to Develop a Bespoke OptiPhageTM Library	Apr. 15	CI
Sondrel wins USD23 million contract	Feb. 27	AN
Fusion Antibodies Lands Antibodies Contract with Diagnostics Company	Feb. 27	MT
Fusion Antibodies plc Receives First Purchase Order Under the Master Services Agreement	Feb. 27	CI
Fusion Antibodies raises GBP1.4 million via placing	Feb. 14	AN
Fusion Antibodies Raises GBP1 Million via Share Issue	Feb. 14	MT
Fusion Antibodies strikes follow-on research and development project	Feb. 06	AN
Fusion Antibodies Receives Follow-On Project from US Biotechnology Client	Feb. 06	MT
AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations	Feb. 06	AN
Fusion Antibodies plc Receives Follow-On Project Award and R&D Update	Feb. 06	CI
Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform	Feb. 01	AN
Fusion Antibodies Receives R&D Tax Credit from UK Government	Feb. 01	MT
FTSE 100 slips as miners hold down index	Dec. 04	AN
Fusion Antibodies shares fall with revenue despite "positive" outlook	Dec. 04	AN
AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations	Dec. 04	AN
Fusion Antibodies plc Reports Earnings Results for the Half Year Ended September 30, 2023	Dec. 04	CI
Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024	Dec. 04	CI
Fusion Antibodies Shares Rise on US Cancer Institute Collaboration	Nov. 28	DJ
Fusion Antibodies shares up on deal with US National Cancer Institute	Nov. 28	AN
AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow	Nov. 28	AN

Chart Fusion Antibodies plc

Duration

Period

More charts

Company Profile

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FUSION ANTIBODIES PLC	-11.76%	4.55M
MODERNA, INC.	+43.34%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research